Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

44.37
+0.02000.05%
Post-market: 43.73-0.6392-1.44%19:30 EDT
Volume:846.60K
Turnover:37.69M
Market Cap:9.16B
PE:-15.75
High:45.12
Open:44.85
Low:44.08
Close:44.35
52wk High:45.42
52wk Low:14.47
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.74
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:12.45
PE(LYR):-16.01

Loading ...

Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million

Reuters
·
Jun 27

S&P 500 Futures Drop in Premarket Trading; on Semiconductor, Davita Lag

Dow Jones
·
Jun 26

Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed

Simply Wall St.
·
Jun 19

Immunovant director Atul Pande disposes of USD 51,030 common shares

Reuters
·
Jun 17

A Look At Immunovant (IMVT) Valuation As IMVT 1402 Trial Engagement Lifts Investor Interest

Simply Wall St.
·
Jun 11

Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?

Simply Wall St.
·
Jun 08

Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million

Reuters
·
May 30

Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
May 30

Immunovant Is Maintained at Buy by Guggenheim

Dow Jones
·
May 26

H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)

TIPRANKS
·
May 26

Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million

Reuters
·
May 23

Immunovant Is Maintained at Hold by Truist Securities

Dow Jones
·
May 22

Immunovant price target raised to $30 from $23 at Truist

TIPRANKS
·
May 22

Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications

TIPRANKS
·
May 22

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Benzinga Earnings
·
May 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Immunovant (IMVT) and Anteris Technologies Global Corp. (AVR)

TIPRANKS
·
May 21

Immunovant (IMVT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 21

Assessing Immunovant (IMVT) Valuation After Strong IMVT-1402 Data And Refocused Pipeline Strategy

Simply Wall St.
·
May 21

Immunovant Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 21

Immunovant, Inc. : H.c. Wainwright Raises Target Price to $40 From $35

THOMSON REUTERS
·
May 21